乳腺癌原发灶与局部复发灶HR、Her-2表达差异及临床意义  

Discordance of HR,Her-2 Receptor Expression Between Primary and Locally Recurrent Focuses of Breast Cancer and Clinical Significance

作　　者：李海平[1] 刘薇[1] 

机构地区：[1]郑州人民医院乳腺外科,河南郑州450000

出　　处：《中外医疗》2014年第10期10-11,13,共3页China & Foreign Medical Treatment

摘　　要：目的通过比较乳腺癌患者原发灶和局部复发灶HR、Her-2表达的差异,分析其临床意义。方法用免疫组化或FISH检测病理确诊的46例乳腺癌患者原发灶和局部复发灶HR、Her-2表达差异情况。结果该研究组中,乳腺癌原发灶雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体-2(Her-2)阳性率分别为69.57%(32/46)、65.22%(30/46)、23.91%(11/46),相应的局部复发灶ER、PR、Her-2的阳性率分别为32.61%(15/46)、26.09%(12/46)、45.65%(21/46)。统计显示,HR、Her-2的表达在原发灶及局部复发灶中差异有统计学意义(P<0.05)。结论乳腺癌原发灶与局部复发灶的HR、Her-2表达存在显著差异,所以对局部复发的乳腺癌患者治疗时,应重新检测其激素状态进而指导治疗。Objective To investigate the discordance of HR, Her-2 receptor expression between primary and locally recurrent fo-cuses of breast cancer, and analyze the clinical significance. Methods Immunohistochemical or FISH test was used to detect the discordance of HR, Her-2 receptor expression between primary and locally recurrent focuses of 46 cases of patients with breast cancer. Results Of this group, the positive rate of ER, PR, Her-2 in primary breast cancer was 69.57%（32/46）, 65.22%（30/46）, 23.91%（11/46）, respectively, and 32.61%（15/46）, 26.09%（12/46）, 45.65%（21/46） in the locally recurrent focuses;the differences in HR, Her-2 expression between primary foci and locally recurrent focuses showed by statistics were statistically significant（P＆lt;0.05）. Conclusion The discordance in expression level of HR and Her-2 receptor between primary and locally recurrent focuses breast cancer was significant. The re-evaluation of hormone and Her-2 receptor in locally recurrent breast cancer was necessary and ben-eficial for the treatment.

关 键 词：乳腺癌 原发灶 激素受体 HER-2受体 

分 类 号：R737.9[医药卫生—肿瘤]